Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) Stock Information | RedChip

Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) Listen to this Section


$1.39
N/A ( 0% ) 7.7K

Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's primary target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derivedĀ from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.

Market Data


Open


$1.39

Previous close


$1.39

Volume


7.7K

Market cap


$19.73M

Day range


$1.36 - $1.45

52 week range


$1.36 - $2.36

Insider Ownership Transactions

Total Amount Purchased: -31,894.00 | $ -44,332.66

Date Type Amount Purchased Purchaser
2024-03-26 Sale -1000.00 Galante Joseph C
2024-03-26 Sale -816.00 Anthony Todd M.
2024-03-26 Sale -445.00 Hamm John M.
2024-03-26 Sale -593.00 Bitterman Chris T.
2024-03-26 Sale -1000.00 Brown Martin S JR
2024-03-26 Sale -1000.00 Young Caroline
2024-03-26 Sale -1186.00 Herman James L
2024-03-26 Sale -25710.00 KAZIMI A J
2023-12-28 Sale -72.00 Jones James
2023-12-28 Sale -72.00 KAZIMI A J

SEC Fillings


Form Type Description Pages Date
10-q Quarterly Reports 59 May 10, 2024
8-k 8K-related 15 May 07, 2024
8-k 8K-related 13 Apr 29, 2024
4 Insider transactions 1 Mar 26, 2024
4 Insider transactions 1 Mar 26, 2024
4 Insider transactions 1 Mar 26, 2024
4 Insider transactions 1 Mar 26, 2024
4 Insider transactions 1 Mar 26, 2024
4 Insider transactions 1 Mar 26, 2024
4 Insider transactions 1 Mar 26, 2024

Latest News


Terms and Agreement

Please agree to the terms to continue using the chat feature.